BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, DeLapaz RL, Lee HJ, Magro CM, Valeri AM. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807-816. [PMID: 18710976 DOI: 10.1148/radiol.2483071863] [Cited by in Crossref: 226] [Cited by in F6Publishing: 151] [Article Influence: 17.4] [Reference Citation Analysis]
Number Citing Articles
1 Garovic VD, Achauer MA, Kittner T, Horák D, Sheng R, Stanson AW. Comparison of gadodiamide-enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of renal artery stenosis: Results of a phase III multicenter trial. J Magn Reson Imaging 2010;31:390-7. [DOI: 10.1002/jmri.22032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
2 Lima XT, Alora-palli MB, Kimball AB, Kay J. Validation of a Screening Instrument for Nephrogenic Systemic Fibrosis. Arthritis Care Res 2013;65:637-42. [DOI: 10.1002/acr.21877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Dibble EH, Swenson DW, Cartagena C, Baird GL, Herliczek TW. Effectiveness of a Staged US and Unenhanced MR Imaging Algorithm in the Diagnosis of Pediatric Appendicitis. Radiology 2018;286:1022-9. [PMID: 29156146 DOI: 10.1148/radiol.2017162755] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bode AS, Planken RN, Merkx MA, van der Sande FM, Geerts L, Tordoir JH, Leiner T. Feasibility of non-contrast-enhanced magnetic resonance angiography for imaging upper extremity vasculature prior to vascular access creation. Eur J Vasc Endovasc Surg. 2012;43:88-94. [PMID: 22070856 DOI: 10.1016/j.ejvs.2011.09.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
5 Takahashi N, Glockner JF, Hartman RP, King BF, Leibovich BC, Stanley DW, Fitz-gibbon PD, Kawashima A. Gadolinium Enhanced Magnetic Resonance Urography for Upper Urinary Tract Malignancy. Journal of Urology 2010;183:1330-6. [DOI: 10.1016/j.juro.2009.12.031] [Cited by in Crossref: 61] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
6 Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2021;298:28-35. [PMID: 33170103 DOI: 10.1148/radiol.2020202903] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
7 Voth M, Haneder S, Huck K, Gutfleisch A, Schönberg SO, Michaely HJ. Peripheral Magnetic Resonance Angiography With Continuous Table Movement in Combination With High Spatial and Temporal Resolution Time-Resolved MRA With a Total Single Dose (0.1 mmol/kg) of Gadobutrol at 3.0 T: . Investigative Radiology 2009;44:627-33. [DOI: 10.1097/rli.0b013e3181b4c26c] [Cited by in Crossref: 49] [Cited by in F6Publishing: 9] [Article Influence: 4.1] [Reference Citation Analysis]
8 Heydari B, Kwong RY, Jerosch-Herold M. Technical advances and clinical applications of quantitative myocardial blood flow imaging with cardiac MRI. Prog Cardiovasc Dis 2015;57:615-22. [PMID: 25727176 DOI: 10.1016/j.pcad.2015.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
9 Bahrami S, Raman SS, Sauk S, Salehmoghaddam S, Villablanca JP, Finn JP, Lu DS. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors. J Comput Assist Tomogr 2009;33:819-23. [PMID: 19940643 DOI: 10.1097/RCT.0b013e31819d68ed] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
10 Ponrartana S, Moore MM, Chan SS, Victoria T, Dillman JR, Chavhan GB. Safety issues related to intravenous contrast agent use in magnetic resonance imaging. Pediatr Radiol 2021;51:736-47. [PMID: 33871726 DOI: 10.1007/s00247-020-04896-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Do JG, Kim YB, Lee DG, Hwang JH. A case of delayed onset nephrogenic systemic fibrosis after gadolinium based contrast injection. Ann Rehabil Med 2012;36:880-6. [PMID: 23342325 DOI: 10.5535/arm.2012.36.6.880] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
12 Gossner J. Is Nephrogenic Systemic Fibrosis Linked to the Introduction of Contrast-enhanced MR Angiography? Radiology 2009;251:612-3. [DOI: 10.1148/radiol.2512082246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
14 Kim HK, Lee GH, Chang Y. Gadolinium as an MRI contrast agent. Future Med Chem 2018;10:639-61. [PMID: 29412006 DOI: 10.4155/fmc-2017-0215] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
15 Renz DM, Durmus T, Böttcher J, Taupitz M, Diekmann F, Huppertz A, Pfeil A, Maurer MH, Streitparth F, Bick U, Hamm B, Fallenberg EM. Comparison of Gadoteric Acid and Gadobutrol for Detection as Well as Morphologic and Dynamic Characterization of Lesions on Breast Dynamic Contrast-Enhanced Magnetic Resonance Imaging: . Investigative Radiology 2014;49:474-84. [DOI: 10.1097/rli.0000000000000039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 2.1] [Reference Citation Analysis]
16 Altun E, Semelka RC, Cakit C. Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol. 2009;16:897-905. [PMID: 19375360 DOI: 10.1016/j.acra.2009.01.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
17 Bruckman MA, Yu X, Steinmetz NF. Engineering Gd-loaded nanoparticles to enhance MRI sensitivity via T(1) shortening. Nanotechnology 2013;24:462001. [PMID: 24158750 DOI: 10.1088/0957-4484/24/46/462001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
18 Martin DR. Nephrogenic Systemic Fibrosis and Gadolinium-Enhanced Magnetic Resonance Imaging: Does a US Food and Drug Administration Alert Influence Practice Patterns in CKD? American Journal of Kidney Diseases 2010;56:427-30. [DOI: 10.1053/j.ajkd.2010.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
19 Elmholdt T, Pedersen M, Jørgensen B, Søndergaard K, Jensen J, Ramsing M, Olesen A. Nephrogenic systemic fibrosis is found only among gadolinium‐exposed patients with renal insufficiency: a case–control study from Denmark. British Journal of Dermatology 2011;165:828-36. [DOI: 10.1111/j.1365-2133.2011.10465.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
20 Fretellier N, Idée JM, Dencausse A, Karroum O, Guerret S, Poveda N, Jestin G, Factor C, Raynal I, Zamia P, Port M, Corot C. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol 2011;46:292-300. [PMID: 21263333 DOI: 10.1097/RLI.0b013e3182056ccf] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
21 Apelqvist J. Diagnostics and treatment of the diabetic foot. Endocrine 2012;41:384-97. [DOI: 10.1007/s12020-012-9619-x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 60] [Article Influence: 10.7] [Reference Citation Analysis]
22 Anderson JD, Epstein FH, Meyer CH, Hagspiel KD, Wang H, Berr SS, Harthun NL, Weltman A, Dimaria JM, West AM, Kramer CM. Multifactorial determinants of functional capacity in peripheral arterial disease: uncoupling of calf muscle perfusion and metabolism. J Am Coll Cardiol 2009;54:628-35. [PMID: 19660694 DOI: 10.1016/j.jacc.2009.01.080] [Cited by in Crossref: 89] [Cited by in F6Publishing: 60] [Article Influence: 7.4] [Reference Citation Analysis]
23 Wiginton CD. Implications of NSF-Active and NSF-Inert in Nephrogenic Systemic Fibrosis. American Journal of Roentgenology 2008;191:1864-6. [DOI: 10.2214/ajr.08.1410] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
24 Hanna RF, Finkelstone LA, Chow DS, Miloushev VZ, Escudero MR, Lagana SM, Prince MR. Nephrogenic systemic fibrosis risk and liver disease. Int J Nephrol 2014;2014:679605. [PMID: 24778878 DOI: 10.1155/2014/679605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
25 Cheong BY, Duran C, Preventza OA, Muthupillai R. Comparison of Low-Dose Higher-Relaxivity and Standard-Dose Lower-Relaxivity Contrast Media for Delayed-Enhancement MRI: A Blinded Randomized Crossover Study. AJR Am J Roentgenol 2015;205:533-9. [PMID: 26295638 DOI: 10.2214/AJR.14.13749] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
26 Perazella MA, Reilly RF. Imaging patients with kidney disease: how do we approach contrast-related toxicity? Am J Med Sci 2011;341:215-21. [PMID: 21139495 DOI: 10.1097/MAJ.0b013e3181f016e6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
27 Valesano JC, Carr CM, Eckel LJ, Carlson ML, Lane JI. MRI screening of the internal auditory canal: Is gadolinium necessary to detect intralabyrinthine schwannomas? Am J Otolaryngol 2018;39:133-7. [PMID: 29273441 DOI: 10.1016/j.amjoto.2017.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
28 Khawaja AZ, Cassidy DB, Al Shakarchi J, McGrogan DG, Inston NG, Jones RG. Revisiting the risks of MRI with Gadolinium based contrast agents-review of literature and guidelines. Insights Imaging. 2015;6:553-558. [PMID: 26253982 DOI: 10.1007/s13244-015-0420-2] [Cited by in Crossref: 111] [Cited by in F6Publishing: 74] [Article Influence: 18.5] [Reference Citation Analysis]
29 Heydari B, Jerosch-Herold M, Kwong RY. Assessment of myocardial ischemia with cardiovascular magnetic resonance. Prog Cardiovasc Dis 2011;54:191-203. [PMID: 22014487 DOI: 10.1016/j.pcad.2011.09.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
30 Li R, Ji Z, Dong J, Chang CH, Wang X, Sun B, Wang M, Liao YP, Zink JI, Nel AE, Xia T. Enhancing the imaging and biosafety of upconversion nanoparticles through phosphonate coating. ACS Nano 2015;9:3293-306. [PMID: 25727446 DOI: 10.1021/acsnano.5b00439] [Cited by in Crossref: 104] [Cited by in F6Publishing: 70] [Article Influence: 17.3] [Reference Citation Analysis]
31 Kunst MM, Schaefer PW. Ischemic stroke. Radiol Clin North Am 2011;49:1-26. [PMID: 21111127 DOI: 10.1016/j.rcl.2010.07.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
32 Martin DR, Krishnamoorthy SK, Kalb B, Salman KN, Sharma P, Carew JD, Martin PA, Chapman AB, Ray GL, Larsen CP, Pearson TC. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010;31:440-6. [PMID: 20099361 DOI: 10.1002/jmri.22024] [Cited by in Crossref: 84] [Cited by in F6Publishing: 57] [Article Influence: 7.6] [Reference Citation Analysis]
33 George SM, Kalantarinia K. The role of imaging in the management of cardiorenal syndrome. Int J Nephrol 2011;2011:245241. [PMID: 21318046 DOI: 10.4061/2011/245241] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
34 Papini GD, Tritella S, Secchi F, Aliprandi A, Di Leo G, Sardanelli F. Myocardial delayed enhancement using a single dose (0.1 mmol/kg) of gadobenate dimeglumine: contrast resolution versus intraventricular blood and viable myocardium. Radiol Med 2010;115:693-701. [PMID: 20221713 DOI: 10.1007/s11547-010-0495-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
35 Uccioli L, Meloni M, Izzo V, Giurato L, Merolla S, Gandini R. Critical limb ischemia: current challenges and future prospects. Vasc Health Risk Manag 2018;14:63-74. [PMID: 29731636 DOI: 10.2147/VHRM.S125065] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 17.7] [Reference Citation Analysis]
36 Altaha MA, Jaskolka JD, Tan K, Rick M, Schmitt P, Menezes RJ, Wintersperger BJ. Non-contrast-enhanced MR angiography in critical limb ischemia: performance of quiescent-interval single-shot (QISS) and TSE-based subtraction techniques. Eur Radiol 2017;27:1218-26. [DOI: 10.1007/s00330-016-4448-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
37 Miller CA, Chowdhary S, Ray SG, Sarma J, Williams SG, Yonan N, Mittal TK, Schmitt M. Role of Noninvasive Imaging in the Diagnosis of Cardiac Allograft Vasculopathy. Circ Cardiovasc Imaging 2011;4:583-93. [DOI: 10.1161/circimaging.110.961425] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
38 Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R. Nephrogenic Systemic Fibrosis. Journal of the American College of Cardiology 2009;53:1621-8. [DOI: 10.1016/j.jacc.2008.12.061] [Cited by in Crossref: 123] [Cited by in F6Publishing: 75] [Article Influence: 10.3] [Reference Citation Analysis]
39 Hope TA, Herfkens RJ, Denianke KS, Leboit PE, Hung Y, Weil E. Nephrogenic Systemic Fibrosis in Patients With Chronic Kidney Disease Who Received Gadopentetate Dimeglumine: . Investigative Radiology 2009;44:135-9. [DOI: 10.1097/rli.0b013e31819343ba] [Cited by in Crossref: 46] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
40 Bruce R, Wentland AL, Haemel AK, Garrett RW, Sadowski DR, Djamali A, Sadowski EA. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Invest Radiol. 2016;51:701-705. [PMID: 26885631 DOI: 10.1097/rli.0000000000000259] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
41 Wermuth PJ, Jimenez SA. Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Clin Exp Immunol 2014;175:113-25. [PMID: 24111526 DOI: 10.1111/cei.12211] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
42 Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens 2009;18:519-25. [PMID: 19623065 DOI: 10.1097/MNH.0b013e3283309660] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
43 Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Med 2021;3:142-50. [PMID: 33604544 DOI: 10.1016/j.xkme.2020.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
44 Takahashi N, Kawashima A, Glockner JF, Hartman RP, Kim B, King BF. MR urography for suspected upper tract urothelial carcinoma. Eur Radiol 2009;19:912-23. [DOI: 10.1007/s00330-008-1228-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
45 Weller A, Barber JL, Olsen ØE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927-37. [DOI: 10.1007/s00467-013-2636-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
46 Okur A, Kantarci M, Karaca L, Yildiz S, Sade R, Pirimoglu B, Keles M, Avci A, Çankaya E, Schmitt P. Non-contrast-enhanced imaging of haemodialysis fistulas using quiescent-interval single-shot (QISS) MRA: a feasibility study. Clinical Radiology 2016;71:244-9. [DOI: 10.1016/j.crad.2015.11.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
47 Barison A, Baritussio A, Cipriani A, De Lazzari M, Aquaro GD, Guaricci AI, Pica S, Pontone G, Todiere G, Indolfi C, Dellegrottaglie S; Working Group on Cardiac Magnetic Resonance of the Italian Society of Cardiology. Cardiovascular magnetic resonance: What clinicians should know about safety and contraindications. Int J Cardiol 2021;331:322-8. [PMID: 33571560 DOI: 10.1016/j.ijcard.2021.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Kitajima K, Maeda T, Watanabe S, Ueno Y, Sugimura K. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. Int J Urol 2012;19:806-11. [PMID: 22571387 DOI: 10.1111/j.1442-2042.2012.03042.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
49 Weng Q, Hu X, Zheng J, Xia F, Wang N, Liao H, Liu Y, Kim D, Liu J, Li F, He Q, Yang B, Chen C, Hyeon T, Ling D. Toxicological Risk Assessments of Iron Oxide Nanocluster- and Gadolinium-Based T1MRI Contrast Agents in Renal Failure Rats. ACS Nano 2019;13:6801-12. [DOI: 10.1021/acsnano.9b01511] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
50 Edelman RR, Koktzoglou I. Noncontrast MR angiography: An update. J Magn Reson Imaging 2019;49:355-73. [PMID: 30566270 DOI: 10.1002/jmri.26288] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 9.7] [Reference Citation Analysis]
51 Lai LM, Cheng JY, Alley MT, Zhang T, Lustig M, Vasanawala SS. Feasibility of ferumoxytol-enhanced neonatal and young infant cardiac MRI without general anesthesia. J Magn Reson Imaging 2017;45:1407-18. [PMID: 27678106 DOI: 10.1002/jmri.25482] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
52 Leiner T, Kucharczyk W. Special issue: nephrogenic systemic fibrosis. J Magn Reson Imaging 2009;30:1233-5. [PMID: 19938034 DOI: 10.1002/jmri.21985] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
53 Lau JF, Weinberg MD, Olin JW. Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis. Nat Rev Cardiol 2011;8:405-18. [PMID: 21629211 DOI: 10.1038/nrcardio.2011.66] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
54 Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol 2017;31:1581-94. [PMID: 28786499 DOI: 10.1111/jdv.14466] [Cited by in Crossref: 42] [Cited by in F6Publishing: 10] [Article Influence: 10.5] [Reference Citation Analysis]
55 Chow DS, Bahrami S, Raman SS, Rotchel S, Sayre JW, Busuttil RW, Lu DS. Risk of nephrogenic systemic fibrosis in liver transplantation patients. AJR Am J Roentgenol. 2011;197:658-662. [PMID: 21862808 DOI: 10.2214/ajr.10.5976] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
56 Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 2011;4:1206-16. [PMID: 22093272 DOI: 10.1016/j.jcmg.2011.08.013] [Cited by in Crossref: 70] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
57 Sun MR, Pedrosa I. Magnetic resonance imaging of renal masses. Semin Ultrasound CT MR 2009;30:326-51. [PMID: 19711644 DOI: 10.1053/j.sult.2009.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
58 Attenberger UI, Morelli JN, Schoenberg SO, Michaely HJ. Assessment of the kidneys: magnetic resonance angiography, perfusion and diffusion. J Cardiovasc Magn Reson 2011;13:70. [PMID: 22085467 DOI: 10.1186/1532-429X-13-70] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
59 Martin DR, Semelka RC, Chapman A, Peters H, Finn PJ, Kalb B, Thomsen H. Nephrogenic systemic fibrosis versus contrast-induced nephropathy: Risks and benefits of contrast-enhanced MR and CT in renally impaired patients. J Magn Reson Imaging 2009;30:1350-6. [DOI: 10.1002/jmri.21968] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
60 Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010;256:735-43. [PMID: 20663970 DOI: 10.1148/radiol.10091131] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
61 Schieda N, Maralani PJ, Hurrell C, Tsampalieros AK, Hiremath S. Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2019;70:226-32. [DOI: 10.1016/j.carj.2019.04.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 16.5] [Reference Citation Analysis]
62 Takehara Y, Yamashita S, Sakahara H, Masui T, Isoda H. Magnetic resonance angiography of the aorta. Ann Vasc Dis 2011;4:271-85. [PMID: 23555465 DOI: 10.3400/avd.di.11.00822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
63 Penfield JG, Reilly RF. Gadolinium and Nephrogenic Systemic Fibrosis: Have We Overreacted?: GADOLINIUM AND NEPHROGENIC SYSTEMIC FIBROSIS. Seminars in Dialysis 2011;24:480-6. [DOI: 10.1111/j.1525-139x.2011.00945.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Longmire MR, Ogawa M, Choyke PL, Kobayashi H. Dendrimers as high relaxivity MR contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2014;6:155-62. [PMID: 24155241 DOI: 10.1002/wnan.1250] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
65 Chrysochou C, Power A, Shurrab AE, Husain S, Moser S, Lay J, Salama AD, Kalra PA. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol. 2010;5:484-489. [PMID: 20093350 DOI: 10.2215/cjn.06580909] [Cited by in Crossref: 53] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
66 Natalin RA, Prince MR, Grossman ME, Silvers D, Landman J. Contemporary applications and limitations of magnetic resonance imaging contrast materials. J Urol 2010;183:27-33. [PMID: 19913804 DOI: 10.1016/j.juro.2009.09.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
67 Gill R, Shapiro R, Kayler LK. Management of peripheral vascular disease compromising renal allograft placement and function: review of the literature with an illustrative case: PVD management in renal transplantation. Clinical Transplantation 2011;25:337-44. [DOI: 10.1111/j.1399-0012.2010.01351.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
68 Newton BB, Jimenez SA. Mechanism of NSF: New evidence challenging the prevailing theory. J Magn Reson Imaging 2009;30:1277-83. [PMID: 19937925 DOI: 10.1002/jmri.21980] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
69 Bui BT, Miller S, Mildenberger P, Sam A, Sheng R. Comparison of contrast-enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of peripheral arterial occlusive disease: Results of a phase III multicenter trial. J Magn Reson Imaging 2010;31:1402-10. [DOI: 10.1002/jmri.22086] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
70 Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN. Nephrogenic Systemic Fibrosis and Its Impact on Abdominal Imaging. RadioGraphics 2009;29:1565-74. [DOI: 10.1148/rg.296095517] [Cited by in Crossref: 66] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
71 Lepäntalo M, Apelqvist J, Setacci C, Ricco JB, de Donato G, Becker F, Robert-Ebadi H, Cao P, Eckstein HH, De Rango P. Chapter V: Diabetic foot. Eur J Vasc Endovasc Surg. 2011;42 Suppl 2:S60-S74. [PMID: 22172474 DOI: 10.1016/s1078-5884(11)60012-9] [Cited by in Crossref: 100] [Cited by in F6Publishing: 18] [Article Influence: 11.1] [Reference Citation Analysis]
72 Bohl S, Schulz-Menger J. Cardiovascular magnetic resonance imaging of non-ischaemic heart disease: established and emerging applications. Heart Lung Circ 2010;19:117-32. [PMID: 20138807 DOI: 10.1016/j.hlc.2009.11.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
73 Jinzaki M, Kitagawa K, Tsai IC, Chan C, Yu W, Yong HS, Choi BW; ASCI CCT & CMR Guideline Working Group. ASCI 2010 contrast media guideline for cardiac imaging: a report of the Asian Society of Cardiovascular Imaging cardiac computed tomography and cardiac magnetic resonance imaging guideline working group. Int J Cardiovasc Imaging 2010;26:203-12. [PMID: 20931289 DOI: 10.1007/s10554-010-9691-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
74 Costelloe CM, Murphy WA Jr, Haygood TM, Kumar R, McEnery KW, Stafford RJ, Roy A, Bassett RL Jr, Harrell RK, Madewell JE. Comparison of half-dose and full-dose gadolinium MR contrast on the enhancement of bone and soft tissue tumors. Skeletal Radiol 2011;40:327-33. [PMID: 20862469 DOI: 10.1007/s00256-010-1028-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
75 Hope TA, High WA, Leboit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, Brasch RC. Nephrogenic Systemic Fibrosis in Rats Treated with Erythropoietin and Intravenous Iron. Radiology 2009;253:390-8. [DOI: 10.1148/radiol.2532090580] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
76 Runge VM. Dechelation (Transmetalation): Consequences and Safety Concerns With the Linear Gadolinium-Based Contrast Agents, In View of Recent Health Care Rulings by the EMA (Europe), FDA (United States), and PMDA (Japan). Invest Radiol 2018;53:571-8. [PMID: 30130320 DOI: 10.1097/RLI.0000000000000507] [Cited by in Crossref: 34] [Cited by in F6Publishing: 2] [Article Influence: 17.0] [Reference Citation Analysis]
77 Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology. 2019;292:376-386. [PMID: 31264946 DOI: 10.1148/radiol.2019182916] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 21.5] [Reference Citation Analysis]
78 Hodnett PA, Ward EV, Davarpanah AH, Scanlon TG, Collins JD, Glielmi CB, Bi X, Koktzoglou I, Gupta N, Carr JC. Peripheral arterial disease in a symptomatic diabetic population: prospective comparison of rapid unenhanced MR angiography (MRA) with contrast-enhanced MRA. AJR Am J Roentgenol. 2011;197:1466-1473. [PMID: 22109304 DOI: 10.2214/ajr.10.6091] [Cited by in Crossref: 45] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
79 Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res 2016;29:627-42. [PMID: 27615400 DOI: 10.1111/pcmr.12538] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 11.4] [Reference Citation Analysis]
80 Edelman RR, Aherne E, Leloudas N, Pang J, Koktzoglou I. Near-isotropic noncontrast MRA of the renal and peripheral arteries using a thin-slab stack-of-stars quiescent interval slice-selective acquisition. Magn Reson Med 2020;83:1711-20. [PMID: 31631387 DOI: 10.1002/mrm.28032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
81 Edelman RR, Koktzoglou I. "Push-button" noncontrast MR angiography using balanced T1 relaxation-enhanced steady-state (bT1RESS). Magn Reson Med 2021;85:1248-57. [PMID: 32936486 DOI: 10.1002/mrm.28492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
82 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 19] [Article Influence: 6.9] [Reference Citation Analysis]
83 Pietsch H, Jost G, Frenzel T, Raschke M, Walter J, Schirmer H, Hütter J, Sieber MA. Efficacy and safety of lanthanoids as X-ray contrast agents. European Journal of Radiology 2011;80:349-56. [DOI: 10.1016/j.ejrad.2009.10.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
84 Karcaaltincaba M, Oguz B, Haliloglu M. Current status of contrast-induced nephropathy and nephrogenic systemic fibrosis in children. Pediatr Radiol 2009;39 Suppl 3:382-4. [PMID: 19440757 DOI: 10.1007/s00247-009-1236-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
85 Pietsch H, Raschke M, Ellinger-ziegelbauer H, Jost G, Walter J, Frenzel T, Lenhard D, Hütter J, Sieber MA. The Role of Residual Gadolinium in the Induction of Nephrogenic Systemic Fibrosis-Like Skin Lesions in Rats: . Investigative Radiology 2011;46:48-56. [DOI: 10.1097/rli.0b013e3181efd49a] [Cited by in Crossref: 35] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
86 Heinz-Peer G, Neruda A, Watschinger B, Vychytil A, Geusau A, Haumer M, Weber M. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. Eur J Radiol 2010;76:129-34. [PMID: 19619969 DOI: 10.1016/j.ejrad.2009.06.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
87 Lin K, Lloyd-Jones DM, Li D, Carr JC. Quantitative imaging biomarkers for the evaluation of cardiovascular complications in type 2 diabetes mellitus. J Diabetes Complications 2014;28:234-42. [PMID: 24309215 DOI: 10.1016/j.jdiacomp.2013.09.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
88 Tsushima Y, Kanal E, Thomsen HS. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. Br J Radiol 2010;83:590-5. [PMID: 20413447 DOI: 10.1259/bjr/17689538] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
89 Hellman RN. Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 2011;31:310-6. [PMID: 21784280 DOI: 10.1016/j.semnephrol.2011.05.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
90 Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function? Radiology 2015;276:741-7. [DOI: 10.1148/radiol.2015142423] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
91 Pietsch H, Lengsfeld P, Steger-Hartmann T, Löwe A, Frenzel T, Hütter J, Sieber MA. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 2009;44:226-33. [PMID: 19252439 DOI: 10.1097/RLI.0b013e3181998eb7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
92 Alabousi M, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis: Radiology In Training. Radiology 2021;300:279-84. [PMID: 34060939 DOI: 10.1148/radiol.2021210044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Weinreb JC, Kuo PH. Nephrogenic Systemic Fibrosis. Magnetic Resonance Imaging Clinics of North America 2009;17:159-67. [DOI: 10.1016/j.mric.2009.01.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
94 Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011;260:105-11. [PMID: 21586680 DOI: 10.1148/radiol.11102340] [Cited by in Crossref: 113] [Cited by in F6Publishing: 70] [Article Influence: 11.3] [Reference Citation Analysis]
95 Toyoda H, Hiraoka A, Tada T, Michitaka K, Takaguchi K, Tsuji K, Itobayashi E, Takizawa D, Hirooka M, Koizumi Y, Ochi H, Joko K, Kisaka Y, Shimizu Y, Tajiri K, Tani J, Taniguchi T, Toshimori A, Fujioka S, Kumada T. Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis. Ther Apher Dial 2017;21:465-72. [PMID: 28880488 DOI: 10.1111/1744-9987.12563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
96 Gwenzi W, Mangori L, Danha C, Chaukura N, Dunjana N, Sanganyado E. Sources, behaviour, and environmental and human health risks of high-technology rare earth elements as emerging contaminants. Science of The Total Environment 2018;636:299-313. [DOI: 10.1016/j.scitotenv.2018.04.235] [Cited by in Crossref: 145] [Cited by in F6Publishing: 74] [Article Influence: 48.3] [Reference Citation Analysis]
97 Lepäntalo M, Fiengo L, Biancari F. Peripheral arterial disease in diabetic patients with renal insufficiency: a review. Diabetes Metab Res Rev 2012;28 Suppl 1:40-5. [PMID: 22271722 DOI: 10.1002/dmrr.2233] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
98 Sato T, Ito K, Tamada T, Kanki A, Watanabe S, Nishimura H, Tanimoto D, Higashi H, Yamamoto A. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: Evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Magnetic Resonance Imaging 2013;31:1412-7. [DOI: 10.1016/j.mri.2013.03.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
99 Bernstein EJ, Schmidt-lauber C, Kay J. Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. Best Practice & Research Clinical Rheumatology 2012;26:489-503. [DOI: 10.1016/j.berh.2012.07.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
100 Voth M, Michaely HJ, Schwenke C, Vos B, Pietsch H. Contrast-enhanced magnetic resonance angiography (MRA): evaluation of three different contrast agents at two different doses (0.05 and 0.1 mmol/kg) in pigs at 1.5 Tesla. Eur Radiol 2011;21:337-44. [DOI: 10.1007/s00330-010-1940-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
101 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 12.3] [Reference Citation Analysis]
102 Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 2009;29:887-94. [PMID: 19306428 DOI: 10.1002/jmri.21708] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
103 Husarik DB, Bashir MR, Weber PW, Nichols EB, Howle LE, Merkle EM, Nelson RC. Contrast-Enhanced Magnetic Resonance Angiography: First-Pass Arterial Enhancement as a Function of Gadolinium-Chelate Concentration, and the Saline Chaser Volume and Injection Rate. Investigative Radiology 2012;47:121-7. [DOI: 10.1097/rli.0b013e3182300603] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
104 Sato T, Tamada T, Watanabe S, Nishimura H, Kanki A, Noda Y, Higaki A, Yamamoto A, Ito K. Tissue gadolinium deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA: evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Radiol med 2015;120:557-62. [DOI: 10.1007/s11547-014-0492-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Bruckman MA, Jiang K, Simpson EJ, Randolph LN, Luyt LG, Yu X, Steinmetz NF. Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus. Nano Lett 2014;14:1551-8. [PMID: 24499194 DOI: 10.1021/nl404816m] [Cited by in Crossref: 109] [Cited by in F6Publishing: 91] [Article Influence: 15.6] [Reference Citation Analysis]
106 Liu H, Zhang J, Chen X, Du XS, Zhang JL, Liu G, Zhang WG. Application of iron oxide nanoparticles in glioma imaging and therapy: from bench to bedside. Nanoscale 2016;8:7808-26. [PMID: 27029509 DOI: 10.1039/c6nr00147e] [Cited by in Crossref: 65] [Cited by in F6Publishing: 17] [Article Influence: 16.3] [Reference Citation Analysis]
107 Ian Paterson D, White JA, Butler CR, Connelly KA, Guerra PG, Hill MD, James MT, Kirpalani A, Lydell CP, Roifman I, Sarak B, Sterns LD, Verma A, Wan D, Crean AM, Grosse-Wortmann L, Hanneman K, Leipsic J, Manlucu J, Nguyen ET, Sandhu RK, Villemaire C, Wald RM, Windram J; Primary Panel., Secondary Panel. 2021 Update on Safety of Magnetic Resonance Imaging: Joint Statement From Canadian Cardiovascular Society/Canadian Society for Cardiovascular Magnetic Resonance/Canadian Heart Rhythm Society. Can J Cardiol 2021;37:835-47. [PMID: 34154798 DOI: 10.1016/j.cjca.2021.02.012] [Reference Citation Analysis]
108 Yantasee W, Fryxell GE, Porter GA, Pattamakomsan K, Sukwarotwat V, Chouyyok W, Koonsiripaiboon V, Xu J, Raymond KN. Novel sorbents for removal of gadolinium-based contrast agents in sorbent dialysis and hemoperfusion: preventive approaches to nephrogenic systemic fibrosis. Nanomedicine 2010;6:1-8. [PMID: 19447204 DOI: 10.1016/j.nano.2009.05.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
109 Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol. 2009;5:157-170. [PMID: 19190625 DOI: 10.1038/ncpneph1040] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
110 Altun E, Martin DR, Wertman R, Lugo-somolinos A, Fuller ER, Semelka RC. Nephrogenic Systemic Fibrosis: Change in Incidence Following a Switch in Gadolinium Agents and Adoption of a Gadolinium Policy—Report from Two U.S. Universities. Radiology 2009;253:689-96. [DOI: 10.1148/radiol.2533090649] [Cited by in Crossref: 112] [Cited by in F6Publishing: 64] [Article Influence: 9.3] [Reference Citation Analysis]
111 Alhadad A, Sterner G, Svensson Å, Alhadad H, Leander P. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden. Scandinavian Journal of Urology and Nephrology 2012;46:48-53. [DOI: 10.3109/00365599.2011.621142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
112 Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol. 2011;56:65-73. [PMID: 21572796 DOI: 10.4103/0019-5154.77556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
113 Secchi F, Iozzelli A, Papini GDE, Aliprandi A, Di Leo G, Sardanelli F. MR imaging of aortic coarctation. Radiol med 2009;114:524-37. [DOI: 10.1007/s11547-009-0386-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
114 Marckmann P, Skov L. Nephrogenic Systemic Fibrosis: Clinical Picture and Treatment. Radiologic Clinics of North America 2009;47:833-40. [DOI: 10.1016/j.rcl.2009.05.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
115 Sieber MA, Steger-hartmann T, Lengsfeld P, Pietsch H. Gadolinium-based contrast agents and NSF: Evidence from animal experience. J Magn Reson Imaging 2009;30:1268-76. [DOI: 10.1002/jmri.21971] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
116 Bardin T, Richette P. Nephrogenic systemic fibrosis. Current Opinion in Rheumatology 2010;22:54-8. [DOI: 10.1097/bor.0b013e328333bf3d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
117 Feng M, Fan YZ, Ma XJ, Li JX, Yang XG. The gadolinium-based contrast agent Omniscan® promotes in vitro fibroblast survival through in situ precipitation. Metallomics 2015;7:1103-10. [PMID: 25867453 DOI: 10.1039/c5mt00055f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
118 Haemel AK, Sadowski EA, Shafer MM, Djamali A. Update on nephrogenic systemic fibrosis: are we making progress?: Update on nephrogenic systemic fibrosis. International Journal of Dermatology 2011;50:659-66. [DOI: 10.1111/j.1365-4632.2010.04851.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
119 Bentley-Hibbert S, Schwartz L. Use of Imaging for GI Cancers. J Clin Oncol 2015;33:1729-36. [PMID: 25918300 DOI: 10.1200/JCO.2014.60.2847] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
120 von der Haar K, Lavrentieva A, Stahl F, Scheper T, Blume C. Lost signature: progress and failures in in vivo tracking of implanted stem cells. Appl Microbiol Biotechnol 2015;99:9907-22. [DOI: 10.1007/s00253-015-6965-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
121 Morris MF, Zhang Y, Zhang H, Prowda JC, Silvers DN, Fawwaz RA, Prince MR. Features of nephrogenic systemic fibrosis on radiology examinations. AJR Am J Roentgenol 2009;193:61-9. [PMID: 19542396 DOI: 10.2214/AJR.08.1352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson Imaging. 2009;30:1298-1308. [PMID: 19937930 DOI: 10.1002/jmri.21973] [Cited by in Crossref: 94] [Cited by in F6Publishing: 68] [Article Influence: 8.5] [Reference Citation Analysis]
123 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol C, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018;69:136-50. [PMID: 29706252 DOI: 10.1016/j.carj.2017.11.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
124 Aburahma AF, Yacoub M. Renal imaging: duplex ultrasound, computed tomography angiography, magnetic resonance angiography, and angiography. Seminars in Vascular Surgery 2013;26:134-43. [DOI: 10.1053/j.semvascsurg.2014.06.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
125 Idée J, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Critical Reviews in Toxicology 2014;44:895-913. [DOI: 10.3109/10408444.2014.955568] [Cited by in Crossref: 66] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
126 Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J. Nephrogenic Systemic Fibrosis after Gadopentetate Dimeglumine Exposure: Case Series of 36 Patients. Radiology 2009;253:81-9. [DOI: 10.1148/radiol.2531082160] [Cited by in Crossref: 76] [Cited by in F6Publishing: 61] [Article Influence: 6.3] [Reference Citation Analysis]
127 Poff JA, Hecht EM, Ramchandani P. Renal Imaging in Patients with Renal Impairment. Curr Urol Rep 2011;12:24-33. [DOI: 10.1007/s11934-010-0158-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
128 Silberzweig JI, Chung M. Removal of gadolinium by dialysis: review of different strategies and techniques. J Magn Reson Imaging 2009;30:1347-9. [PMID: 19937933 DOI: 10.1002/jmri.21981] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
129 Langer RD, Lorke DE, Neidl van Gorkom KF, Petroianu G, Azimullah S, Nurulain SM, Singh S, Fuchsjäger M. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. Eur J Radiol 2012;81:2562-7. [PMID: 22304979 DOI: 10.1016/j.ejrad.2011.10.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
130 Zou Z, Ma L, Li H. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital. J Magn Reson Imaging 2009;30:1309-12. [DOI: 10.1002/jmri.21769] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
131 Zhang HL, Sos TA, Winchester PA, Gao J, Prince MR. Renal Artery Stenosis: Imaging Options, Pitfalls, and Concerns. Progress in Cardiovascular Diseases 2009;52:209-19. [DOI: 10.1016/j.pcad.2009.10.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
132 So K, Macquillan GC, Adams LA, Delriviere L, Mitchell A, Moody H, Wood DJ, Junckerstorff RC, Jeffrey GP. Malignant fibrous histiocytoma complicating nephrogenic systemic fibrosis post liver transplantation. Intern Med J. 2009;39:613-617. [PMID: 19769682 DOI: 10.1111/j.1445-5994.2009.01977.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
133 Jalandhara N, Arora R, Batuman V. Nephrogenic Systemic Fibrosis and Gadolinium-Containing Radiological Contrast Agents: An Update. Clin Pharmacol Ther 2011;89:920-3. [DOI: 10.1038/clpt.2010.346] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
134 Li B, Li Q, Chen C, Guan Y, Liu S. Diagnostic accuracy of computer tomography angiography and magnetic resonance angiography in the stenosis detection of autologuous hemodialysis access: a meta-analysis. PLoS One 2013;8:e78409. [PMID: 24194928 DOI: 10.1371/journal.pone.0078409] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
135 Mathur M, Jones JR, Weinreb JC. Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist’s Primer. RadioGraphics 2020;40:153-62. [DOI: 10.1148/rg.2020190110] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 28.0] [Reference Citation Analysis]
136 Walker JP, Nosova E, Sigovan M, Rapp J, Grenon MS, Owens CD, Gasper WJ, Saloner DA. Ferumoxytol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation of lower extremity arterial disease. Ann Vasc Surg 2015;29:63-8. [PMID: 25269682 DOI: 10.1016/j.avsg.2014.09.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
137 Girardi M, Kay J, Elston DM, Leboit PE, Abu-alfa A, Cowper SE. Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. Journal of the American Academy of Dermatology 2011;65:1095-1106.e7. [DOI: 10.1016/j.jaad.2010.08.041] [Cited by in Crossref: 124] [Cited by in F6Publishing: 83] [Article Influence: 12.4] [Reference Citation Analysis]
138 Akita H, Jinzaki M, Akita A, Mikami S, Oya M, Kuribayashi S. Renal cell carcinoma in patients with acquired cystic disease of the kidney: Assessment using a combination of T2-weighted, diffusion-weighted, and chemical-shift MRI without the use of contrast material: MRI for RCC in Patients With ACDK. J Magn Reson Imaging 2014;39:924-30. [DOI: 10.1002/jmri.24226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
139 Ward EV, Galizia MS, Usman A, Popescu AR, Dunkle E, Edelman RR. Comparison of quiescent inflow single-shot and native space for nonenhanced peripheral MR angiography. J Magn Reson Imaging 2013;38:1531-8. [PMID: 23564638 DOI: 10.1002/jmri.24124] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
140 Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T, Suzuki K, Oshima H, Hara M, Shibamoto Y. Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology. 2009;251:112-121. [PMID: 19332849 DOI: 10.1148/radiol.2511080873] [Cited by in Crossref: 228] [Cited by in F6Publishing: 152] [Article Influence: 19.0] [Reference Citation Analysis]
141 Pietsch H, Pering C, Lengsfeld P, Walter J, Steger-hartmann T, Golfier S, Frenzel T, Hütter J, Weinmann H, Sieber MA. Evaluating the role of zinc in the occurrence of fibrosis of the skin: A preclinical study. J Magn Reson Imaging 2009;30:374-83. [DOI: 10.1002/jmri.21845] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
142 Mayr M, Burkhalter F, Bongartz G. Nephrogenic systemic fibrosis: Clinical spectrum of disease. J Magn Reson Imaging 2009;30:1289-97. [DOI: 10.1002/jmri.21975] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
143 Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis 2010;55:S1-13; quiz S14-9. [PMID: 20420966 DOI: 10.1053/j.ajkd.2009.10.056] [Cited by in Crossref: 56] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
144 Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188-198. [PMID: 21531325 DOI: 10.1053/j.ackd.2011.03.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
145 Fretellier N, Idée J, Bruneval P, Guerret S, Daubiné F, Jestin G, Factor C, Poveda N, Dencausse A, Massicot F, Laprévote O, Mandet C, Bouzian N, Port M, Corot C. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol 2012;165:1151-62. [PMID: 21740412 DOI: 10.1111/j.1476-5381.2011.01585.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
146 Keunen O, Taxt T, Grüner R, Lund-Johansen M, Tonn JC, Pavlin T, Bjerkvig R, Niclou SP, Thorsen F. Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. Adv Drug Deliv Rev 2014;76:98-115. [PMID: 25078721 DOI: 10.1016/j.addr.2014.07.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
147 Jones RA, Votaw JR, Salman K, Sharma P, Lurie C, Kalb B, Martin DR. Magnetic resonance imaging evaluation of renal structure and function related to disease: Technical review of image acquisition, postprocessing, and mathematical modeling steps. J Magn Reson Imaging 2011;33:1270-83. [DOI: 10.1002/jmri.22335] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
148 Soulez G, Bloomgarden DC, Rofsky NM, Smith MP, Abujudeh HH, Morgan DE, Lichtenstein RJ, Schiebler ML, Wippold FJ 2nd, Russo C, Kuhn MJ, Mennitt KW, Maki JH, Stolpen A, Liou J, Semelka RC, Kirchin MA, Shen N, Pirovano G, Spinazzi A. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. AJR Am J Roentgenol. 2015;205:469-478. [PMID: 26295633 DOI: 10.2214/ajr.14.14268] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
149 Forghani R. Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns. Top Magn Reson Imaging 2016;25:163-9. [PMID: 27367314 DOI: 10.1097/RMR.0000000000000095] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
150 Feng Y, Emerson L, Jeong EK, Parker DL, Lu ZR. Application of a biodegradable macromolecular contrast agent in dynamic contrast-enhanced MRI for assessing the efficacy of indocyanine green-enhanced photothermal cancer therapy. J Magn Reson Imaging 2009;30:401-6. [PMID: 19629979 DOI: 10.1002/jmri.21838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
151 Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69:661-668. [PMID: 24582176 DOI: 10.1016/j.crad.2014.01.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 39] [Article Influence: 11.1] [Reference Citation Analysis]